Vegf Fosters The Growth Of Mesothelioma Tumors By Supplying Them With Extra Nutrients

Recently There are two mesothelioma studies have been completed

, The results show that anti-angiogenesis drugs can not bring significant treatment effect on patients.

An anti-angiogenesis drug is a substance that inhibits the growth of new blood vessels (angiogenesis). It is a new targeting Treatment strategies. The anti-angiogenesis therapy has presently become one of hot topics of anti-tumor research and anti-angiogenesis drug screening has also become an important method to find new anti-tumor drugs. This "anti-angiogenesis" drug has also been used with some success in breast cancer. Although the anti-proliferation drugs can kill tumor cells, The vasculature surrounding the tumor provide blood to them. So that Residual tumor cells can continue to grow. This will have to be borne out in further studies, but if we can normalize the vasculature surrounding the tumor, we will have a better chance of eradicating the tumor. According to his theory, by introducing drugs that stop the formation of new blood vessels (anti-angiogenesis) tumors would not get the nourishment they need and would be unable to continue growing. This theory has attracted a lot of attention and investment in mesothelioma research.

Substance was found in 1989 and called it vascular endothelial growth factor, or VEGF (pronounced VEJ-eff). VEGF fosters the growth of tumors by supplying them with extra nutrients. In 1995 antibody-based drugs that could neutralize the effects of VEGF were already in development, so we were able to use these to test our approach in mice. A recently published article reported on a phase II study of the oral VEGF receptor tyrosine kinase inhibitor called cediranib. Cediranib was administered to 54 malignant pleural mesothelioma patients after they received platinum-based systemic chemotherapy. cediranib monotherapy has modest single-agent activity in malignant pleural mesothelioma after platinum-based therapy. similar to other angiogenesis inhibitors, has limited activity in malignant pleural mesothelioma.

According to the National Cancer Institute, there are at least four anti-angiogenesis clinical trials currently recruiting mesothelioma patients for additional mesothelioma research. These include: 1) Avastin Plus Pemetrexed-cisplatin Study, 2) Axitinib in Malignant Mesothelioma, 3) Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901), 4) Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy.

by: zhaowei

POST COMMENT

Plumbing Piedmont: Specialist Skilled Manpower Functioning Of Venture Capital Bb Guns Are Excellent Toy Guns For Boys Four Things To Look For In A Vocal Coach Free Text Messages Walk On Roads Fearlessly With A Freedom From Accidents: Plan Your Princess Birthday Parties Different Ram Specifications To Increase The Speed Of Your Pc Yoga For Beginners - An Overview - Stress Elimination Grab Your Chance To Be Famous With Your Biography: 201 Stainless Steel- Banding Tools Explained Bathroom Furniture: An Intrinsic Range To Exemplify Decor Press Release Distribution Tips